Thomas  Wilder net worth and biography

Thomas Wilder Biography and Net Worth

Director of Penumbra
Thomas C. Wilder has served on the Board since January 2017. Since August 2017, Mr. Wilder has served as the President and Chief Executive Officer of Neuros Medical, Inc., a neuromodulation company. From February 2010 through July 2016, Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies. From April 2006 to 2009, Mr. Wilder served as the President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients. From 2002 to 2006, he served as the President and CEO of MicroTherapeutics, Inc. (MTIX), a company also focused on the neurovascular space. Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division. Mr. Wilder began his career in the Financial Statement Audit Practice of Price Waterhouse, where he worked from 1986 to 1989. He received a B.A. from Stanford University and an M.B.A. from Northwestern University’s Kellogg Graduate School of Management.

What is Thomas Wilder's net worth?

The estimated net worth of Thomas Wilder is at least $75,881.20 as of August 7th, 2023. Mr. Wilder owns 340 shares of Penumbra stock worth more than $75,881 as of March 29th. This net worth evaluation does not reflect any other investments that Mr. Wilder may own. Learn More about Thomas Wilder's net worth.

How do I contact Thomas Wilder?

The corporate mailing address for Mr. Wilder and other Penumbra executives is One Penumbra Place, Alameda CA, 94502. Penumbra can also be reached via phone at (510) 748-3200 and via email at [email protected]. Learn More on Thomas Wilder's contact information.

Has Thomas Wilder been buying or selling shares of Penumbra?

Thomas Wilder has not been actively trading shares of Penumbra in the last ninety days. Most recently, Thomas Wilder sold 340 shares of the business's stock in a transaction on Monday, August 7th. The shares were sold at an average price of $253.48, for a transaction totalling $86,183.20. Following the completion of the sale, the director now directly owns 340 shares of the company's stock, valued at $86,183.20. Learn More on Thomas Wilder's trading history.

Who are Penumbra's active insiders?

Penumbra's insider roster includes Arani Bose (Insider), Adam Elsesser (CEO), Harpreet Grewal (Director), Don Kassing (Director), Bridget O'Rourke (Director), James Pray (Insider), Johanna Roberts (EVP), Surbhi Sarna (Director), and Thomas Wilder (Director). Learn More on Penumbra's active insiders.

Are insiders buying or selling shares of Penumbra?

In the last twelve months, insiders at the sold shares 28 times. They sold a total of 86,209 shares worth more than $24,304,275.51. The most recent insider tranaction occured on March, 4th when Director Arani Bose sold 7,500 shares worth more than $1,876,500.00. Insiders at Penumbra own 5.3% of the company. Learn More about insider trades at Penumbra.

Information on this page was last updated on 3/4/2024.

Thomas Wilder Insider Trading History at Penumbra

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/7/2023Sell340$253.48$86,183.20340View SEC Filing Icon  
1/4/2023Sell124$223.64$27,731.36214View SEC Filing Icon  
10/3/2022Sell124$191.20$23,708.80338View SEC Filing Icon  
7/5/2022Sell248$123.64$30,662.72462View SEC Filing Icon  
7/12/2021Sell161$275.09$44,289.49View SEC Filing Icon  
1/4/2021Sell115$174.32$20,046.80148View SEC Filing Icon  
10/1/2020Sell115$196.06$22,546.90View SEC Filing Icon  
7/13/2020Sell230$192.47$44,268.10View SEC Filing Icon  
1/2/2020Sell118$164.16$19,370.88238View SEC Filing Icon  
7/15/2019Sell237$169.92$40,271.04View SEC Filing Icon  
7/11/2018Sell304$138.50$42,104.00View SEC Filing Icon  
1/2/2018Sell345$91.15$31,446.75View SEC Filing Icon  
10/2/2017Sell345$90.20$31,119.00View SEC Filing Icon  
7/18/2017Sell345$86.10$29,704.50View SEC Filing Icon  
See Full Table

Thomas Wilder Buying and Selling Activity at Penumbra

This chart shows Thomas Wilder's buying and selling at Penumbra by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Penumbra Company Overview

Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $223.18
Low: $222.71
High: $228.43

50 Day Range

MA: $248.16
Low: $220.06
High: $273.27

2 Week Range

Now: $223.18
Low: $180.93
High: $348.67

Volume

387,503 shs

Average Volume

396,705 shs

Market Capitalization

$8.64 billion

P/E Ratio

96.62

Dividend Yield

N/A

Beta

0.52